Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals



– Alar’s Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD – RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ — Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop,…

Leave a Reply